ASCO 2011 Olaparib and Cabozantinib are two new products to watch

The countdown is underway for the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7th.  Over 30,000 attendees are expected and more than 4,000 abstracts will be presented.

What’s hot at the meeting is what everyone is asking?  Sally Church is preparing a video blog (vlog) with her thoughts that will be posted on Pharma Strategy Blog soon.

In the meantime, two new products to watch out for are:

Cabozantinib (XL184).  This new product from Exelixis may have potential in advanced prostate cancer with phase II data showing a dramatic effect on bone metastases, making it a potential competitor to denosumab.  You can read more about the ASCO data on Biotech Strategy Blog.

Olaparib.  Just when we thought that PARP inhibitors were ineffective after the failure of iniparib in breast cancer, there’s dramatic data at ASCO showing AstraZeneca’s olaparib prolongs remission in serious ovarian cancer.  You can read more on Pharma Strategy Blog.

The focus of ASCO 2011 is “Patients, Pathways, Progress”. We’ll be writing more about the meeting over the next few weeks, so do check back for more details.

, , , , , , , , , , , , , , ,

error: Content is protected !!